AI Terminal
Xlife Sciences AG
Report Publication Announcement • Apr 21, 2022
1041_rns_2022-04-21_5a5bf037-2667-4da8-b52e-89362c7ead5e.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 21 April 2022 07:01
Xlife Sciences: Date of publication Annual Report 2022
Xlife Sciences AG / Key word(s): Annual Results
21-Apr-2022 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Xlife Sciences AG (SIX: XLS) today announced that due to the change from the Munich Stock Exchange (unregulated market [‘Freiverkehr’] to the regulated market of the SIX Swiss Exchange (SME Segment ‘Sparks’) and the related change of auditors, the company will publish its annual report 2021 newly on 29 April 2022.
Financial calendar
Annual Report 2022
Valuation Report
Ordinary General Assembly 2022 2022 Half-Year Results
Contact
April 29, 2022
May 9, 2022
June 20, 2022 September 28, 2022
Information for journalists:
IRF Reputation AG,
Valentin Handschin, [email protected]
Information for investors:
Dennis Lennartz, [email protected]
Xlife Sciences AG
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
E-Mail: [email protected]
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Börsen: SIX Swiss Exchange
About Xlife Sciences AG (SIX: XLS)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch
Disclaimer
Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.
End of ad hoc announcement
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | [email protected] |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1331497 |
| End of Announcement | EQS News Service |